Up-regulation of the NER proteins in tumours has repeatedly been associated with a worse prognosis with decreased ERCC1 mRNA/protein levels leading to an improved response to CDDP-based chemotherapy, and survival, in patients with metastatic lung cancer [13], head and neck squamous cell carcinoma [14], as well as of ovarian [15], gastric [16] and bladder cancers [17]. The gene discussed is ERCC1; the disease is neoplasm.